BioNTech and Genevant Sciences Sign Strategic mRNA-Focused Partnership in Rare Diseases
BioNTech AG and Genevant Sciences today announced that they have entered into a collaboration to develop five mRNA therapeutic programs for rare diseases with high unmet medical need. The companies have also agreed a series of exclusive licenses covering the application of Genevant’s delivery technology to five of BioNTech’s oncology programs. Genevant is eligible to receive significant commercial milestones for the oncology licenses.
The collaboration in rare diseases will combine Genevant’s industry-leading lipid nanoparticle (LNP) delivery technology with BioNTech’s cutting-edge mRNA drug discovery platform to develop best-in-class therapeutics. Both companies have established GMP-grade manufacturing capabilities and infrastructure.
Under the terms of the agreement, Genevant and BioNTech will pursue the co-development and co-commercialization of five mRNA programs. Genevant and BioNTech will share all future costs and profits for these programs on a 50/50 basis. The companies aim to initiate clinical development in 2020.
In addition to its strengths in cell and gene therapies and protein therapeutics, BioNTech is an industry leader in mRNA therapy development with extensive scientific expertise, manufacturing infrastructure, broad academic networks, and a deep understanding of mechanisms of action and clinical applications for this technology. It also has an innovative, scalable, ‘just-in-time’ manufacturing capability to produce its tailored treatments for patients.
“This partnership with Genevant will allow us to access a highly potent, clinically validated LNP delivery platform,” said Prof. Ugur Sahin, Co-Founder and Chief Executive Officer of BioNTech. “Genevant’s liver-targeted platform complements our existing capabilities for dendritic cell-specific delivery of mRNA encoded antigens used in the development of our cancer vaccine pipeline.”
Genevant’s LNP platform is the only clinically-validated LNP delivery technology, the safety and efficacy of which has been evaluated in over 400 patients across multiple clinical programs. Genevant’s delivery technologies can facilitate therapeutic approaches covering a broad spectrum of payloads. Genevant has begun development on numerous programs across multiple RNA modalities.
“This 50/50 partnership to develop rare disease mRNA therapeutics recognizes the critical importance of both best-in-class nucleic acids and their delivery in RNA drug development,” said Paris Panayiotopoulos, Executive Chairman of Genevant. “BioNTech’s impressive molecular design expertise and Genevant’s leadership in RNA delivery are the ideal combination for developing cutting edge mRNA therapies for rare disease patients who have limited or no treatment options today.”
BioNTech is Europe’s largest privately-held biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases. The Company combines all building blocks for individualized immunotherapy under one roof – from diagnostics and drug development to manufacturing. Its cutting-edge technologies range from individualized mRNA-based medicines through innovative chimeric antigen receptors and T-cell receptor-based products to novel checkpoint immunomodulators and small molecules. BioNTech’s commercial approach is validated by five top-tier corporate partnerships with Genentech, Genmab, Eli Lilly, Sanofi and Bayer Animal Health and its scientific approach through over 60 peer-reviewed scientific publications, including five publications in Nature. Founded in 2008, BioNTech’s financial shareholders include the Struengmann Family Office as its majority shareholder, Fidelity Management & Research Company, Invus, Janus Henderson Investors, MIG Fonds, Redmile Group, Salvia and several European family offices.
For more information, see www.biontech.de.
About Genevant Sciences
Genevant Sciences aims to deliver innovative and clinically meaningful therapies that improve the lives of patients with genetic disorders by developing products in-house and forming partnerships to build a diverse pipeline of RNA therapeutics across multiple modalities. Through its proprietary delivery platforms, Genevant is able to pursue mRNA, RNAi, and gene editing modalities and select the optimal approach for any given disease.
Genevant expects to have 5 to 10 RNA programs in the clinic by 2020 targeting a range of genetic disorders with limited or no treatment options. For more information, please visit www.genevant.com.
Genevant Sciences, Inc.
Kunal Kishnani, +1 (646) 822-8568
Chief of Staff and Head of Operations
International Media & European Investor Enquiries:
Consilium Strategic Communications
Mary-Jane Elliott / Sukaina Virji, +44 (0)20 3709 5700
US Investor Enquiries:
John Woolford, +1 (443) 213-0506
German Media Enquiries:
Gretchen Schweitzer / Dr. Stephanie May, +40 (0)89 23 88 77 30
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
NavVis Achieves Breakthough 6D SLAM Indoor LiDAR Mapping With Velodyne’s 3D LiDAR Sensor20.9.2018 14:43 | Pressemelding
On April 18th, 2018, NavVis released their M6, a fully-integrated, cart-based system designed for large-scale indoor mapping. The M6 utilizes VLP-16 sensors by Velodyne LiDAR, Inc., which allows it to produce a 3D map of the surrounding environment. Six cameras capture 360° immersive imagery and photorealistic point-clouds, resulting in high-resolution mapped images. NavVis developed this product in response to their customers’ request for a more versatile and sophisticated system which could be used effectively with uneven terrain. In addition to AEC professionals, construction companies and manufacturers can also draw benefits from the higher data quality provided by this enhanced innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180920005560/en/ NavVis M6 is a fully-integrated, cart-based system designed for large-scale indoor mapping. (Photo: Business Wire) The M6 was developed by NavVis after customers requeste
Steve Bannon’s New Documentary Film Trump @War Launches Free Online Access20.9.2018 14:34 | Pressemelding
Trump @War in conjunction with its online distribution partner, The Western Journal, is pleased to announce that the full length HD feature film Trump @War is free and available to viewers worldwide at Trumpmovienow.com. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180920005553/en/ Watch free full-length feature film: trumpmovienow.com (Photo: Business Wire) “The Western Journal does great work and we are happy they are partnering with us,” stated Stephen K. Bannon. “It’s a film that every American, regardless of political belief, should watch. It’s a historic time for our country, and no one should be sitting on the sidelines during the upcoming elections.” Directed by Bannon and produced by Dan Fleuette, Trump @War is a retelling of the most significant election campaign in modern U.S. history and a look forward to the high-stakes midterm election in November 2018, which will cement President Trump’s legacy. “Steve Banno
GTIS Partners Grabs Top Spots in Prestigious GRESB Sustainability Ranking20.9.2018 14:24 | Pressemelding
GTIS Partners LP (“GTIS”), a real assets investment firm headquartered in New York City, with offices in São Paulo, Los Angeles, San Francisco, Atlanta, Paris and Munich, today announced that the GTIS Brazil Real Estate Fund (“GTIS Brazil Real Estate Fund I”) has been recognized as 2018’s most sustainable private equity real estate investment fund in South America by the Global Real Estate Sustainability Benchmark (GRESB). This is the fourth year running the fund has clinched the top ranking. GTIS Brazil Real Estate Funds II and III took second- and third-place honors, respectively, matching the funds’ 2017 survey rankings. “Our across-the-board top-place rankings are a testament to the day-in, day-out efforts of the entire GTIS Brazil team, who’ve incorporated environmental, social and governance principles into their investment and management practices,” said Josh Pristaw, Senior Managing Director, Head of Capital Markets and Co-head of Brazil at GTIS Partners. “What we’re most proud
Medicrea Announces Eurospine 2018 Presence and Highlights a Recently Published Study Validating Its Predictive Modelling Approach for AIS Patients20.9.2018 13:07 | Pressemelding
The Medicrea Group (Euronext Growth Paris: FR0004178572 – ALMED, PEA-PME eligible, and OTCQX: MNRTY and MNRTF), pioneering the transformation of spinal surgeries through Artificial Intelligence, predictive modeling and patient specific implants with its UNiD™ ASI (Adaptive Spine Intelligence) technology, announced today that the Company is attending the Eurospine 2018 meeting taking place in Barcelona, Spain, from September 19th to 21st, where UNiD™ LAB biomedical engineers will showcase the most recent developments of the Company’s UNiD™ ASI technology. Denys Sournac, President and Chief Executive Officer, stated, “At Eurospine 2018, our team of biomedical engineers will show attending spine surgeons how the UNiD™ASI technology answers the gap left by traditional implant manufacturers through a demonstration of the UNiD™ HUB, a software platform that fully integrates surgical planning through machine learning to generate personalized implants that are adapted to each individual patien
Seoul Semiconductor Wins LED Bulb Litigation and Pursuit of Further Enforcement Actions against LED Lighting Retailers20.9.2018 13:00 | Pressemelding
Seoul Semiconductor (KOSDAQ:046890) (collectively with Seoul Viosys Co., Ltd., “Seoul”), a leading global innovator of LED products and technology, announced that the U.S. Federal District Court for Nevada issued a judgment in favor of Seoul against Philcor T.V. & Electronic Leasing, Inc. dba energyavenue.com (“Philcor”), a company that sells LED lighting products. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180920005043/en/ Seoul Semiconductor's Key Patented Technologies (Graphic: Business Wire) Previously, Seoul filed a patent infringement lawsuit in Nevada District Court against Philcor asserting infringement of 8 LED patents. In the lawsuit, Philcor acknowledged that LED products used in the accused products were manufactured by several third party suppliers and, although previously unknown to Philcor, Philcor did not dispute that those products infringed Seoul Semiconductor’s patents. Philcor also did not dispute the
2018 Busan One Asia Festival to Take Place October 20-2820.9.2018 11:00 | Pressemelding
BUSAN METROPOLITAN CITY announced that the Busan One Asia Festival (BOF) will be held from October 20th to 28th in Busan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180920005024/en/ The Busan One Asia Festival (BOF) will be held from October 20th to 28th in Busan. BOF will open with a spectacular BOF Opening Performance on October 20th and end with the BOF Closing Performance on the 28th, both will be at the Busan Asiad Main Stadium. During the opening event, EXO, Wanna One, SEVENTEEN, NCT 127, Mamamoo, EXID, GFriend, and Celeb Five will show up and present wonderful K-POP performances. The closing event will have a colorful finale with performances by Red Velvet, NCT Dream, Favorite, Dynamic Duo and Rhythm Power. The photo is 2017 Busan One Asia Festival BOF Opening Performance. (Photo: Business Wire) BOF will open with a spectacular ‘BOF Opening Performance’ on October 20th and end with the ‘BOF Closing Performance’ on